Ulrich Spengler

Ulrich Spengler's AcademicInfluence.com Rankings

Ulrich Spengler

Physics

#6394

World Rank

#8335

Historical Rank

physics Degrees

Download Badge

Physics

Why Is Ulrich Spengler Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Ulrich Spengler's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy (2009) (1941)
Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF- beta production (1991) (585)
Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection (2003) (565)
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. (2006) (564)
Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: A placebo‐controlled trial (1992) (410)
Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study (2000) (410)
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment‐naïve patients (2008) (371)
Long‐term efficacy of tenofovir monotherapy for hepatitis B virus‐monoinfected patients after failure of nucleoside/nucleotide analogues (2010) (346)
Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. (2010) (345)
A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. (2010) (343)
Tenofovir for patients with lamivudine‐resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy (2006) (303)
Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C (2005) (257)
Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta‐analysis of individual participant data (2014) (211)
Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience (2006) (197)
Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort (2016) (197)
Tumor necrosis factor α in the pathogenesis of human and murine fulminant hepatic failure (2000) (190)
[Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection]. (2018) (185)
IL28B, HLA-C, and KIR Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort: A Cross-Sectional Study (2011) (184)
norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. (2017) (176)
The HLA-A2 restricted T cell epitope HCV core 35-44 stabilizes HLA-E expression and inhibits cytolysis mediated by natural killer cells. (2005) (175)
Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. (1996) (168)
Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B. (1991) (165)
"Atypical p-ANCA" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. (2000) (161)
HIV and hepatitis C virus co-infection. (2004) (159)
Serum selenium, plasma glutathione (GSH) and erythrocyte glutathione peroxidase (GSH-Px)-levels in asymptomatic versus symptomatic human immunodeficiency virus-1 (HIV-1)-infection (1997) (156)
Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection (1995) (156)
Interleukin 6/gp130‐dependent pathways are protective during chronic liver diseases (2003) (156)
Interferon-lambda serum levels in hepatitis C. (2011) (155)
HIV-1 Infection Leads to Increased HLA-E Expression Resulting in Impaired Function of Natural Killer Cells (2005) (146)
T‐ and B‐cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti‐ hepatitis C virus—positive blood donors without viremi (1996) (145)
Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease (2015) (144)
p-ANCAs in autoimmune liver disorders recognise human β-tubulin isotype 5 and cross-react with microbial protein FtsZ (2009) (140)
Correlation of serum concentrations of cystatin C and creatinine to inulin clearance in liver cirrhosis. (2000) (139)
Direct antiviral agents (DAAs) ‐ A new age in the treatment of hepatitis C virus infection (2017) (139)
NK cells from HCV-infected patients effectively induce apoptosis of activated primary human hepatic stellate cells in a TRAIL-, FasL- and NKG2D-dependent manner (2012) (136)
Natural killer p46High expression defines a natural killer cell subset that is potentially involved in control of hepatitis C virus replication and modulation of liver fibrosis (2012) (128)
Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus (2004) (126)
Bleeding Complications after Percutaneous Liver Biopsy (2003) (125)
CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T lymphocytes. (1997) (125)
Plasmid DNA expressing a secreted or a nonsecreted form of hepatitis C virus nucleocapsid: comparative studies of antibody and T-helper responses following genetic immunization. (1997) (123)
Bleeding complications after percutaneous liver biopsy. An analysis of risk factors. (2003) (121)
Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals. (2017) (119)
Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis. (1999) (118)
Hepatitis after chronic abuse of senna (1991) (114)
Hepatic levels of bile acids in end-stage chronic cholestatic liver disease. (1996) (114)
The PNPLA3 rs738409 148M/M Genotype Is a Risk Factor for Liver Cancer in Alcoholic Cirrhosis but Shows No or Weak Association in Hepatitis C Cirrhosis (2011) (113)
Early up‐regulation of chemokine expression in fulminant hepatic failure (2003) (111)
Antiretroviral drug toxicity -- a challenge for the hepatologist? (2002) (110)
Frequency of the HIV-protective CC chemokine receptor 5-Δ32/Δ32 genotype is increased in hepatitis C (2002) (107)
Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. (2017) (106)
The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. (2008) (104)
Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease (1992) (103)
Budesonide in previously untreated autoimmune hepatitis (2005) (103)
Regulation of CC chemokine receptor 5 in Hepatitis G virus infection (2003) (102)
MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C (2016) (101)
Comparison between modified Dixon MRI techniques, MR spectroscopic relaxometry, and different histologic quantification methods in the assessment of hepatic steatosis (2015) (100)
Immunopathogenesis in hepatitis C virus cirrhosis. (2007) (99)
Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis. (2011) (99)
Management of drug‐to‐drug interactions between cyclosporine A and the protease‐inhibitor lopinavir/ritonavir in liver‐transplanted HIV‐infected patients (2004) (99)
Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal. (1998) (97)
Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. (2013) (96)
Atypical antineutrophil cytoplasmic antibodies with perinuclear fluorescence in chronic inflammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins (1998) (93)
Cell activation by synthetic lipopeptides of the hepatitis C virus (HCV)--core protein is mediated by toll like receptors (TLRs) 2 and 4. (2002) (92)
Biliary strictures and recurrence after liver transplantation for primary sclerosing cholangitis: A retrospective multicenter analysis (2016) (91)
Serum selenium versus lymphocyte subsets and markers of disease progression and inflammatory response in human immunodeficiency virus-1 infection (2007) (90)
Interferon/antioxidant combination therapy for chronic hepatitis C--a controlled pilot trial. (1999) (89)
Gallbladder motility before and after extracorporeal shock-wave lithotripsy. (1989) (88)
Imbalanced intrahepatic expression of interleukin 12, interferon gamma, and interleukin 10 in fulminant hepatitis B (2002) (88)
Tumor necrosis factor alpha in the pathogenesis of human and murine fulminant hepatic failure. (2000) (88)
Hepatitis C virus E2 and CD81 interaction may be associated with altered trafficking of dendritic cells in chronic hepatitis C (2006) (86)
Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort (2011) (86)
Decreased frequency of HCV core-specific peripheral blood mononuclear cells with type 1 cytokine secretion in chronic hepatitis C. (1999) (84)
Low-molecular weight proteins as markers for glomerular filtration rate. (2001) (83)
Influence of protease inhibitor therapy on lipoprotein metabolism (1999) (83)
IFN-λ3, not IFN-λ4, likely mediates IFNL3–IFNL4 haplotype–dependent hepatic inflammation and fibrosis (2017) (83)
Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes (2016) (82)
Enhanced expression of CD80 (B7-1), CD86 (B7-2), and CD40 and their ligands CD28 and CD154 in fulminant hepatic failure. (1999) (82)
Antiretroviral triple therapy decreases HIV viral load but does not alter hepatitis C virus (HCV) serum levels in HIV-HCV-co-infected haemophiliacs. (1998) (79)
Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol‐related cirrhosis (2018) (79)
Differential expression of MHC class II subregion products on bile duct epithelial cells and hepatocytes in patients with primary biliary cirrhosis (1988) (79)
Treatment of acute hepatitis C infection in HIV‐infected patients: a retrospective analysis of eleven cases (2005) (79)
Induction of Interleukin-6 by Hepatitis C Virus Core Protein in Hepatitis C–Associated Mixed Cryoglobulinemia and B-Cell Non–Hodgkin's Lymphoma (2006) (78)
Increased peripheral CD4+ regulatory T cells persist after successful direct-acting antiviral treatment of chronic hepatitis C. (2017) (77)
Efficient Culture Adaptation of Hepatitis C Virus Recombinants with Genotype-Specific Core-NS2 by Using Previously Identified Mutations (2010) (77)
Hepatitis C virus NS2 protein inhibits gene expression from different cellular and viral promoters in hepatic and nonhepatic cell lines. (2003) (76)
Compartment-specific distribution of human intestinal innate lymphoid cells is altered in HIV patients under effective therapy (2017) (76)
Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study (2017) (75)
Intrahepatic IL-8 producing Foxp3⁺CD4⁺ regulatory T cells and fibrogenesis in chronic hepatitis C. (2013) (75)
The toll‐like receptor 2 (TLR2) ‐196 to ‐174 del/ins polymorphism affects viral loads and susceptibility to hepatocellular carcinoma in chronic hepatitis C (2012) (73)
Atypical p-ANCA in PSC and AIH: A Hint Toward a “leaky gut”? (2009) (73)
Endotoxin and tumor necrosis factor-receptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt (2011) (73)
Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma (2019) (71)
Impaired CD4⁺ T cell stimulation of NK cell anti-fibrotic activity may contribute to accelerated liver fibrosis progression in HIV/HCV patients. (2013) (71)
Triple therapy with amantadine in treatment‐naive patients with chronic hepatitis C: A placebo‐controlled trial (2003) (70)
Semiquantitative analysis of intrahepatic cytokine mRNAs in chronic hepatitis C. (1997) (69)
T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C virus--positive blood donors without viremia. (1996) (69)
The HLA-E(R)/HLA-E(R) genotype affects the natural course of hepatitis C virus (HCV) infection and is associated with HLA-E-restricted recognition of an HCV-derived peptide by interferon-gamma-secreting human CD8(+) T cells. (2009) (68)
FibroGENE: A gene-based model for staging liver fibrosis. (2016) (68)
Differentiation of antineutrophil nuclear antibodies in inflammatory bowel and autoimmune liver diseases from antineutrophil cytoplasmic antibodies (p‐ANCA) using immunofluorescence microscopy (2001) (68)
Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection. (2004) (67)
Escitalopram for the Prevention of Peginterferon-α2a–Associated Depression in Hepatitis C Virus–Infected Patients Without Previous Psychiatric Disease (2012) (66)
Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers (2020) (65)
[Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C]. (2012) (63)
Inadequate Erythropoietin Response to Anaemia in HIV Patients: Relationship to Serum Levels of Tumour Necrosis Factor‐Alpha, Interleukin‐6 and Their Soluble receptors (1997) (62)
Genetic Analyses Reveal a Role for Vitamin D Insufficiency in HCV-Associated Hepatocellular Carcinoma Development (2013) (62)
Inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) expression in fulminant hepatic failure. (2002) (62)
Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1–infected patients (2009) (61)
Targeting of hepatitis C virus core protein for MHC I or MHC II presentation does not enhance induction of immune responses to DNA vaccination. (1999) (59)
Genetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIV-positive patients with acute and chronic hepatitis C. (2011) (58)
Circulating MicroRNAs as a marker for liver injury in human immunodeficiency virus patients (2015) (58)
Impact of Rifaximin on the Frequency and Characteristics of Spontaneous Bacterial Peritonitis in Patients with Liver Cirrhosis and Ascites (2014) (57)
Is the increase in serum cystathionine levels in patients with liver cirrhosis a consequence of impaired homocysteine transsulfuration at the level of gamma-cystathionase? (2000) (57)
Escape from HLA-B*08-Restricted CD8 T Cells by Hepatitis C Virus Is Associated with Fitness Costs (2008) (56)
An effective interferon‐gamma‐mediated inhibition of hepatitis C virus replication by natural killer cells is associated with spontaneous clearance of acute hepatitis C in human immunodeficiency virus‐positive patients (2014) (56)
Spontaneous bacterial peritonitis: The clinical challenge of a leaky gut and a cirrhotic liver. (2015) (55)
Frequency of the HIV-protective CC chemokine receptor 5-Delta32/Delta32 genotype is increased in hepatitis C. (2002) (54)
MBOAT 7 rs 641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C (2016) (53)
Interferon-λ4 (IFNL4) Transcript Expression in Human Liver Tissue Samples (2013) (53)
The Burden of Hepatitis E among Patients with Hematological Malignancies: a Retrospective European Cohort Study. (2019) (52)
Altered adrenergic responsiveness of endothelium-denuded hepatic arteries and portal veins in patients with cirrhosis. (1999) (52)
Regulatory CD4+ T cells modulate the interaction between NK cells and hepatic stellate cells by acting on either cell type. (2015) (52)
Antigen-specific cytokine response to hepatitis C virus core epitopes in HIV/hepatitis C virus-coinfected patients. (1999) (51)
Antibiotic resistance in healthcare‐related and nosocomial spontaneous bacterial peritonitis (2017) (51)
Liver fibrosis in HIV: which role does HIV itself, long-term drug toxicities and metabolic changes play? (2014) (51)
Semiquantitative analysis of intrahepatic CC-chemokine mRNas in chronic hepatitis C. (2004) (51)
HCV-specific cytokine induction in monocytes of patients with different outcomes of hepatitis C. (2002) (50)
CD8+ T-cell response promotes evolution of hepatitis C virus nonstructural proteins. (2011) (50)
Reduced CC chemokine receptor (CCR) 1 and CCR5 surface expression on peripheral blood T lymphocytes from patients with chronic hepatitis C infection. (2002) (49)
Isolated tuberculosis of the pancreas masquerading as a pancreatic mass. (1995) (49)
Liver histopathology in patients with concurrent chronic hepatitis C and HIV infection (1997) (48)
Effects of HCV co-infection on apoptosis of CD4+ T-cells in HIV-positive patients. (2009) (48)
Natural cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC) is not impaired in patients suffering from chronic hepatitis C. (2001) (47)
T lymphocytes from patients with primary biliary cirrhosis produce reduced amounts of lymphotoxin, tumor necrosis factor and interferon-gamma upon mitogen stimulation. (1992) (47)
Mixed-strain infection with a drug-sensitive and multidrug-resistant strain of Mycobacterium tuberculosis (1995) (47)
Hepatitis C in the patient with human immunodeficiency virus infection. (1998) (47)
Immune responses in hepatitis C virus infection. (1996) (46)
Single and repeated moderate consumption of native or dealcoholized red wine show different effects on antioxidant parameters in blood and DNA strand breaks in peripheral leukocytes in healthy volunteers: a randomized controlled trial [ISRCTN68505294] (2005) (46)
Binding of HCV E2 to CD81 induces RANTES secretion and internalization of CC chemokine receptor 5 (2004) (46)
Effect of the interleukin‐6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients (2007) (46)
Hepatitis C virus core protein induces fibrogenic actions of hepatic stellate cells via toll-like receptor 2 (2011) (45)
Renal functional reserve and nitric oxide in patients with compensated liver cirrhosis (1997) (45)
Core-specific adaptive regulatory T-cells in different outcomes of hepatitis C. (2010) (45)
Semi-quantification of human C-C chemokine mRNAs with reverse transcription/real-time PCR using multi-specific standards. (2000) (44)
Estimation of glomerular filtration rates after orthotopic liver transplantation: Evaluation of cystatin C–based equations (2006) (44)
The treatment of patients with HIV. (2010) (43)
Hepatobiliary magnetic resonance imaging in patients with liver disease: correlation of liver enhancement with biochemical liver function tests (2014) (43)
IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. (2014) (43)
P0772 : Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease: Interim results of a multicenter compassionate use program (2015) (42)
GB virus C coinfection in advanced HIV type-1 disease is associated with low CCR5 and CXCR4 surface expression on CD4+ T-cells (2010) (42)
[Prophylaxis, diagnosis and therapy of hepatitis-C-virus (HCV) infection: the German guidelines on the management of HCV infection - AWMF-Register-No.: 021/012]. (2018) (42)
The CXCR3(+)CD56Bright Phenotype Characterizes a Distinct NK Cell Subset with Anti-Fibrotic Potential That Shows Dys-Regulated Activity in Hepatitis C (2012) (42)
SERUM LEVELS AND IN SITU EXPRESSION OF TNF-α AND TNF-α BINDING PROTEINS IN INFLAMMATORY LIVER DISEASES (1996) (42)
Intrahepatic mRNA expression in hepatitis C virus and HIV/hepatitis C virus co-infection: infiltrating cells, cytokines, and influence of HAART (2008) (41)
Orthotopic liver transplantation in human immunodeficiency virus (HIV)‐positive patients: Outcome of 7 patients from the Bonn cohort (2005) (41)
Effects of the CCR5-Δ32 mutation on antiviral treatment in chronic hepatitis C (2003) (40)
TH1 to TH2 Shift of Cytokines in Peripheral Blood of HIV‐Infected Patients Is Detectable by Reverse Transcriptase Polymerase Chain Reaction but Not by Enzyme‐Linked Immunosorbent Assay Under Nonstimulated Conditions (2000) (40)
Intrahepatic mRNA levels of interferon gamma and tumor necrosis factor alpha and response to antiviral treatment of chronic hepatitis C. (2001) (40)
The ratio of calprotectin to total protein as a diagnostic and prognostic marker for spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites (2015) (40)
Genetic Variation in IL 28 B and Treatment-induced Clearance of Hepatitis C Virus in HIV-Positive Patients With Acute and Chronic Hepatitis C (2011) (39)
CC-chemokine receptor 5 (CCR5) in hepatitis C--at the crossroads of the antiviral immune response? (2004) (39)
Anomalous expression of costimulatory molecules B7-1, B7-2 and CD28 in primary biliary cirrhosis. (1997) (38)
Diagnostic accuracy of atypical p-ANCA in autoimmune hepatitis using ROC- and multivariate regression analysis. (2004) (38)
The IL‐1 system in HIV infection: peripheral concentrations of IL‐1β, IL‐1 receptor antagonist and soluble IL‐1 receptor type II (1997) (37)
Contractile hyporesponsiveness of hepatic arteries in humans with cirrhosis: Evidence for a receptor‐specific mechanism (2001) (36)
Serum antibodies against the hepatitis C virus E2 protein mediate antibody-dependent cellular cytotoxicity (ADCC). (2005) (36)
Prospective evaluation of a clinical score for 60-day mortality after transjugular intrahepatic portosystemic stent-shunt: Bonn TIPSS early mortality analysis (2002) (36)
Placebo‐controlled trial of 400 mg amantadine combined with peginterferon alfa‐2a and ribavirin for 48 weeks in chronic hepatitis C virus‐1 infection (2008) (36)
Polymorphisms in melanoma differentiation‐associated gene 5 link protein function to clearance of hepatitis C virus (2015) (35)
Role of auto-antibodies for the diagnosis of chronic cholestatic liver diseases (2005) (35)
Anti-apoptotic function of gelsolin in fas antibody-induced liver failure in vivo. (2006) (34)
IgA class antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and autoimmune hepatitis (2003) (34)
Cancer risk in HIV-infected individuals on HAART is largely attributed to oncogenic infections and state of immunocompetence (2011) (34)
Genome-wide Association Study for Alcohol-related Cirrhosis Identifies Risk Loci in MARC1 and HNRNPUL1. (2020) (33)
Soluble TNF-Alpha-Receptors I Are Prognostic Markers in TIPS-Treated Patients with Cirrhosis and Portal Hypertension (2013) (33)
Enhancement of antibody dependent cellular cytotoxicity (ADCC) by combination of cytokines. (1999) (32)
Nitrite and nitrate levels in patients with cirrhosis of the liver: influence of kidney function and fasting state. (1999) (32)
Ribavirin Exerts Differential Effects on Functions of Cd4+ Th1, Th2, and Regulatory T Cell Clones in Hepatitis C (2012) (31)
The tandem-repeat polymorphism of the DC-SIGNR gene does not affect the susceptibility to HIV infection and the progression to AIDS. (2003) (31)
Challenges and controversies in haemophilia care in adulthood (2009) (31)
Immune response of peripheral blood mononuclear cells to HBx‐antigen of hepatitis B virus (1991) (31)
TH1 to TH2 shift of cytokines in peripheral blood of HIV-infected patients is detectable by reverse transcriptase polymerase chain reaction but not by enzyme-linked immunosorbent assay under nonstimulated conditions. (2000) (30)
Formation of iso-ursodeoxycholic acid during administration of ursodeoxycholic acid in man. (1991) (30)
Lower copy numbers of the chemokine CCL3L1 gene in patients with chronic hepatitis C. (2010) (30)
Clonal analysis of liver-derived T cells of patients with primary biliary cirrhosis. (1989) (30)
Retreatment of Patients who Failed Daa-Combination Therapies: Real-World Experience from a Large Hepatitis C Resistance Database (2016) (29)
A comparative study of different enzyme immunosorbent assays for human tumor necrosis factor-α (1996) (29)
Allelic Variation in the TNF‐β Gene Does Not Explain the Low TNF‐β Response in Patients With Primary Biliary Cirrhosis (1991) (28)
The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection (2011) (28)
A placebo-controlled randomised trial of budesonide for primary biliary cholangitis following an insufficient response to UDCA. (2020) (28)
989 BUDESONIDE 3MG TID IS SUPERIOR TO PREDNISONE IN COMBINATION WITH AZATHIOPRINE IN THE TREATMENT OF AUTOIMMUNE HEPATITIS (2008) (27)
Cholestasis associated with mesalazine therapy in a patient with Crohn's disease. (1997) (27)
Antiviral therapy for hepatitis C virus recurrence after liver transplantation in HIV-infected patients: outcome in the Bonn cohort (2007) (26)
Deterioration of cholestasis after endoscopic retrograde cholangiography in advanced primary sclerosing cholangitis. (1992) (26)
Sex-specific effects of TLR9 promoter variants on spontaneous clearance of HCV infection (2016) (26)
The predictive value of IL28B gene polymorphism for spontaneous clearance in a single source outbreak cohort is limited in patients carrying the CCR5Δ32 mutation. (2011) (25)
Semiquantitation of intrahepatic MDR3 mRNA levels by reverse transcription/competitive polymerase chain reaction. (1997) (24)
A farnesoid X receptor polymorphism predisposes to spontaneous bacterial peritonitis. (2014) (24)
Comparative study of NK cell-mediated cytotoxicity using radioactive and flow cytometric cytotoxicity assays. (2005) (24)
IL 28 B , HLA-C , and KIR Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort : A Cross-Sectional Study (2011) (24)
Autoimmune Hepatitis – Sequel of a Relapsing Hepatitis A in a 75-Year-Old Woman (2005) (23)
Regulation of NK cell trafficking by CD81 (2009) (23)
Hepatitis C Coinfection Enhances Sensitization of CD4+ T-Cells Towards Fas-Induced Apoptosis in Viraemic and Haart-Controlled HIV-1-Positive Patients (2011) (23)
The tandem‐repeat polymorphism of the DC‐SIGNR gene in HCV infection (2006) (23)
Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double‐blinded multicentre trial (2014) (23)
A common polymorphism in the NCAN gene is associated with hepatocellular carcinoma in alcoholic liver disease. (2014) (22)
Lymphocyte proliferation and apoptosis in HIV-seropositive and healthy subjects during long-term ingestion of fruit juices or a fruit-vegetable-concentrate rich in polyphenols and antioxidant vitamins (2004) (22)
Combined antiretroviral therapy attenuates hepatic extracellular matrix remodeling in HIV patients assessed by novel protein fingerprint markers (2014) (22)
Changing role of invasive aspergillosis in AIDS--a case control study. (1998) (21)
Renal function in the postoperative period after orthotopic liver transplantation. (1992) (21)
Serum levels and in situ expression of TNF-alpha and TNF-alpha binding proteins in inflammatory liver diseases. (1996) (21)
Intrahepatic activation of caspases in human fulminant hepatic failure (2006) (21)
Intrahepatic MxA expression is correlated with interferon‐alpha expression in chronic and fulminant hepatitis (2001) (21)
The CCR5Δ32 allele is associated with reduced liver inflammation in hepatitis C virus infection (2004) (21)
73 A MULTICENTER ANALYSIS OF ANTIVIRAL RESPONSE AFTER ONE YEAR OF TENOFOVIR MONO-THERAPY IN HBV-MONOINFECTED PATIENTS WITH PRIOR NUCLEOS(T)IDE ANALOG EXPERIENCE (2008) (21)
Vitamin E status in patients with liver cirrhosis: normal or deficient? (1999) (21)
Retreatment with Interferon-Alpha and Ribavirin in Primary Interferon-Alpha Non-Responders with Chronic Hepatitis C (2000) (21)
Plasma antioxidant capacity of HIV-seropositive and healthy subjects during long-term ingestion of fruit juices or a fruit–vegetable-concentrate containing antioxidant polyphenols (2001) (21)
TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients (2012) (21)
Management of progressive outer retinal necrosis with cidofovir in a human immunodeficiency virus-infected patient. (1999) (21)
Successful Therapy of a Multidrug-Resistant Extended-Spectrum β-Lactamase-Producing and Fluoroquinolone-Resistant Salmonella enterica Subspecies enterica Serovar Typhi Infection Using Combination Therapy of Meropenem and Fosfomycin. (2017) (20)
Influence of the CXCL1 rs4074 A Allele on Alcohol Induced Cirrhosis and HCC in Patients of European Descent (2013) (20)
Detection of IGF2BP3, HOXB7, and NEK2 mRNA Expression in Brush Cytology Specimens as a New Diagnostic Tool in Patients with Biliary Strictures (2012) (20)
The combination of interleukin-2 and interferon effectively augments the antibody-dependent cellular cytotoxicity of monoclonal antibodies 17-1A and BR55-2 against the colorectal carcinoma cell line HT29 (1998) (20)
Evidence for extensive genotypic diversity and recombination of GB virus C (GBV‐C) in Germany (2011) (20)
Selective Pressures of HLA Genotypes and Antiviral Therapy on Human Immunodeficiency Virus Type 1 Sequence Mutation at a Population Level (2007) (19)
Long-term benzimidazole treatment of alveolar echinococcosis with hematogenic subcutaneous and bone dissemination (2003) (19)
Induction of murine liver damage by overexpression of CD40 ligand provides an experimental model to study fulminant hepatic failure (2006) (19)
Relative Ascites Polymorphonuclear Cell Count Indicates Bacterascites and Risk of Spontaneous Bacterial Peritonitis (2017) (19)
Intrahepatic Expression of Interleukin-1 and Tumor Necrosis Factora in Chronic Hepatitis C (1999) (19)
Improvement of sarcoidosis under therapy with interferon-alpha 2b for chronic hepatitis B virus infection. (1999) (19)
Orthotopic Liver Transplantation in Human-Immunodeficiency-Virus-Positive Patients in Germany (2012) (19)
ROC analysis comparison of three assays for the detection of antibodies against double-stranded DNA in serum for the diagnosis of systemic lupus erythematosus. (2004) (19)
The conservative and interventional treatment of the complications of liver cirrhosis: Part 2 of a series on liver cirrhosis. (2013) (19)
Increased frequency of CD8+ CD45R0+ memory T lymphocytes in acute hepatitis B virus infection. (1993) (19)
Gallbladder emptying is an important factor in fragment disappearance after shock wave lithotripsy. (1993) (19)
Portal hypertension is associated with increased mRNA levels of vasopressor G‐protein‐coupled receptors in human hepatic arteries (2003) (19)
The CXCL1 rs4074 A allele is associated with enhanced CXCL1 responses to TLR2 ligands and predisposes to cirrhosis in HCV genotype 1-infected Caucasian patients. (2012) (18)
Clinical outcomes of HIV-HCV co-infection in a large cohort of hemophiliac patients. (2005) (18)
Indication, outcome and follow up of intensive care in patients with HIV-infection. (2000) (18)
Variation in IFNL4 genotype and response to interferon-based therapy of hepatitis C in HIV-positive patients with acute and chronic hepatitis C (2013) (17)
Real‐world experience with daclatasvir plus sofosbuvir ± ribavirin for post‐liver transplant HCV recurrence and severe liver disease (2017) (17)
The transforming growth factor-β high-producer genotype is associated with response to hepatitis C virus-specific therapy in HIV-positive patients with acute hepatitis C (2008) (17)
Splenic abscesses and abdominal tuberculosis in patients with AIDS. (1996) (17)
Efficacy and safety of an intravenous monoclonal anti-HBs in chronic hepatitis B patients. (2001) (17)
E-cadherin expression is homogeneously reduced in adenoma from patients with familial adenomatous polyposis: an immunohistochemical study of E-cadherin, β-catenin and cyclooxygenase-2 expression (2004) (17)
The lignocaine metabolite (MEGX) liver function test and P-450 induction in humans. (1998) (17)
Nephrogenic diabetes insipidus in a patient taking cidofovir (1997) (17)
Detection of human aspartyl (asparaginyl) beta-hydroxylase and homeobox B7 mRNA in brush cytology specimens from patients with bile duct cancer. (2006) (17)
Relationship between cytochrome P‐450 induction by rifampicin, hepatic volume and portal blood flow in man (1997) (17)
Distribution and effects of polymorphic RANTES gene alleles in HIV/HCV coinfection -- a prospective cross-sectional study. (2005) (17)
α1-Antitrypsin PiMZ heterozygosity has an independent aggravating effect on liver fibrosis in alcoholic liver disease (2014) (17)
Vanishing bile duct syndrome associated with elevated pancreatic enzymes after short-term administration of amoxicillin. (2002) (17)
Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-&agr; and ribavirin: results from a randomized, placebo-controlled, double-blind trial (2007) (16)
Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants. (2019) (16)
Susceptibility to chronic hepatitis C virus infection is influenced by sequence differences in immunodominant CD8+ T cell epitopes. (2013) (16)
Hepatitis C‐associated autoimmunity in patients coinfected with HIV (2005) (16)
Postinfantile giant cell hepatitis with autoimmune features following a human herpesvirus 6-induced adverse drug reaction. (2005) (16)
The effect of hemodialysis on liver stiffness measurement: a single-center series (2013) (16)
Liver stiffness regression after successful Hepatitis C treatment is independent of HIV coinfection (2019) (16)
A frequent keratin 8 p.L227L polymorphism, but no point mutations in keratin 8 and 18 genes, in patients with various liver disorders (2004) (16)
Novel Rat Model of Repetitive Portal Venous Embolization Mimicking Human Non-Cirrhotic Idiopathic Portal Hypertension (2016) (16)
Elevated soluble tumor necrosis factor receptor 75 concentrations identify patients with liver cirrhosis at risk of death. (2008) (16)
The CCR5Delta32 allele is associated with reduced liver inflammation in hepatitis C virus infection. (2004) (16)
Lipidation of T helper sequences from hepatitis C virus core significantly enhances T‐cell activity in vitro (2001) (16)
Amanita phalloides intoxications in a family of russian immigrants. Case reports and review of the literature with a focus on orthotopic liver transplantation. (1994) (16)
Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial. (2000) (16)
Comparison of GB virus C, HIV, and HCV infection markers in hemophiliacs exposed to non-inactivated or inactivated factor concentrates. (2005) (16)
Effects of the CCR5-Delta32 mutation on antiviral treatment in chronic hepatitis C. (2003) (16)
Partial remission of a newly diagnosed diffuse large B‐cell non‐Hodgkin's lymphoma in a hemodialysis patient after administration of immuno‐chemotherapy with rituximab‐CHOP (2007) (15)
Interferon-antibodies and the breakthrough phenomenon during ribavirin/interferon-alpha combination therapy and interferon-alpha monotherapy of patients with chronic hepatitis C. (1999) (15)
HLA class I allele associations with HCV genetic variants in patients with chronic HCV genotypes 1a or 1b infection. (2010) (15)
Renal impairment after liver transplantation - a pilot trial of calcineurin inhibitor-free vs. calcineurin inhibitor sparing immunosuppression in patients with mildly impaired renal function after liver transplantation (2009) (15)
Do λ-IFNs IL28A and IL28B act on human natural killer cells? (2011) (15)
1047 EARLY VERSUS DELAYED TREATMENT OF ACUTE HEPATITIS C: THE GERMAN HEP-NET ACUTE HCV-III STUDY – A RANDOMIZED CONTROLLED TRIAL (2009) (15)
The cytotoxic lymphocyte antigen 4 polymorphisms affect response to hepatitis C virus-specific therapy in HIV(+) patients with acute and chronic hepatitis C virus co-infection (2010) (15)
The low‐dose monoethylglycinexylidide test: Assessment of liver function with fewer side effects (1997) (15)
Bacteremia Caused by a Novel Helicobacter Species in a 28-Year-Old Man with X-Linked Agammaglobulinemia (2010) (15)
Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany. (2018) (15)
The Development and Outcome of Acute‐on‐Chronic Liver Failure After Surgical Interventions (2019) (15)
Hepatitis C virus-derived lipopeptides differentially induce epitope-specific immune responses in vitro. (2004) (15)
Phospholipid autoantibodies and the antiphospholipid antibody syndrome: diagnostic accuracy of 23 methods studied by variation in ROC curves with number of clinical manifestations. (2002) (15)
Six weeks of sofosbuvir/ledipasvir (SOF/LDV) are sufficient to treat acute hepatitis C virus genotype 1 monoinfection: The HepNet Acute HCV IV Study (2016) (14)
CD3(+)CD56(+) Natural Killer-Like T Cells Display Anti-HCV Activity but Are Functionally Impaired in HIV(+) Patients With Acute Hepatitis C (2015) (14)
Management of end-stage liver disease in HIV/hepatitis C virus co-infection. (2011) (14)
Adenovirus-induced liver necrosis in a case of AIDS (1997) (14)
Fatal Pneumonia in an AIDS Patient Coinfected with Adenovirus and Pneumocystis carinii (2000) (14)
Expression of Urotensin II and Its Receptor in Human Liver Cirrhosis and Fulminant Hepatic Failure (2010) (13)
Overweight HIV patients with abdominal fat distribution treated with protease inhibitors are at high risk for abnormalities in glucose metabolism - a reason for glycemic control. (2008) (13)
A hepatitis C virus (HCV) core protein derived peptide inhibits HCV specific lymphocyte proliferation. (2000) (13)
The GNB3 C825T polymorphism affects response to HCV therapy with pegylated interferon in HCV/HIV co-infected but not in HCV mono-infected patients. (2007) (13)
Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections. (2019) (12)
Norursodeoxycholic Acid Improves Cholestasis in Primary Sclerosing Cholangitis: Results of a Phase II Dose Finding Study (2016) (12)
Results of a randomised controlled trial of budesonide add-on therapy in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid (2018) (12)
A variant in the nuclear dot protein 52kDa gene increases the risk for spontaneous bacterial peritonitis in patients with alcoholic liver cirrhosis. (2016) (12)
Alterations of the NK cell pool in HIV/HCV co-infection (2017) (12)
Protein levels of interleukin-12 p70 holomer, its p40 chain and interferon-gamma during advancing HIV infection. (1998) (12)
Human immunodeficiency virus and hepatitis C virus coinfection. (1998) (12)
Bolus Ingestion But Not Regular Consumption of Native or Dealcoholized Red Wine Modulates Selected Immunological Functions of Leukocytes in Healthy Volunteers (2008) (11)
A common polymorphism in the NCAN gene is associated with hepatocellular carcinoma in alcoholic liver disease (2014) (11)
Genetic polymorphisms associated with fatty liver disease and fibrosis in HIV positive patients receiving combined antiretroviral therapy (cART) (2017) (11)
Low-density lipoprotein receptor variants are associated with spontaneous and treatment-induced recovery from hepatitis C virus infection. (2009) (11)
HIV mono-infection is associated with an impaired anti-hepatitis C virus activity of natural killer cells (2015) (11)
A comparative study of different enzyme immunosorbent assays for human tumor necrosis factor-alpha. (1996) (11)
Prediction of imminent complications in HIV-1-infected patients by markers of lymphocyte apoptosis. (2000) (11)
Intrahepatic expression of interleukin-1beta and tumor necrosis factor-alpha in chronic hepatitis C. (1999) (11)
Prediction of Imminent Complications in HIV‐1‐Infected Patients by Markers of Lymphocyte Apoptosis (2000) (11)
Combinations of the cytokines IL-12, IL-2 and IFN-alpha significantly augment whereas the cytokine IL-4 suppresses the cytokine-induced antibody-dependent cellular cytotoxicity of monoclonal antibodies 17-1A and BR55-2. (2000) (11)
C-EDGE IBLD: Efficacy and Safety of Elbasvir/Grazoprevir (EBR/GZR) in Subjects with Chronic Hepatitis C Virus Infection and Inherited Blood Disorders (2016) (10)
MicroRNA-155 is upregulated in ascites in patients with spontaneous bacterial peritonitis (2017) (10)
Triple therapy with amantadine sulphate plus ribavirin and interferon-alpha in previously untreated patients with chronic hepatitis C: results of a double-blind, placebo-controlled trial (2002) (10)
The ATG16L1 Gene Variant rs2241880 (p.T300A) Is Associated With Susceptibility to HCC In Patients with Cirrhosis (2019) (10)
Frequent detection of cell‐associated HIV‐1 RNA in patients with plasma viral load <50 copies/ml (2007) (10)
CD27(+)CD56Bright natural killer cells may be involved in spontaneous clearance of acute hepatitis C in HIV-positive patients (2014) (10)
Elevated Soluble Tumour Necrosis Factor Receptor Serum Concentrations and Short-Term Mortality in Liver Cirrhosis without Acute Infections (2000) (10)
Failure of double protease inhibitor therapy as a salvage therapy for HIV-infected patients resistant to conventional triple therapy. (1999) (10)
Keratin 18 provides resistance to Fas‐mediated liver failure in mice (2009) (10)
Successful thrombolysis after prosthetic pulmonary valve obstruction under aspirin monotherapy. (1997) (10)
Rapid Determination of the Δ32 Deletion in the Human CC-Chemokine Receptor 5 (CCR5) Gene without DNA Extraction by LightCycler Real-Time Polymerase Chain Reaction (2004) (10)
Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation (2018) (10)
Flow cytometric analysis of peptide binding to major histocampatibility complex class I for hepatitis C virus core T-cell epitopes. (2000) (10)
Hypoxia impairs anti-viral activity of natural killer (NK) cells but has little effect on anti-fibrotic NK cell functions in hepatitis C virus infection. (2015) (10)
Hepatic microcirculation: a critical but neglected factor for the outcome of viral hepatitis. (2009) (10)
Interferon- l rs12979860 genotype and liver ﬁbrosis in viral and non-viral chronic liver disease (2015) (9)
Yttrium-90 radioembolization of unresectable hepatocellular carcinoma – a single center experience (2017) (9)
Acenocoumarol Is Not a Safe Alternative for Anticoagulation in Phenprocoumon-Induced Hepatic Failure (2003) (9)
Changes of lymphocyte apoptosis associated with sequential introduction of highly active antiretroviral therapy (2003) (9)
Spontaneous bacterial peritonitis by Pasteurella multocida under treatment with rifaximin (2014) (9)
Endogenous levels of C-C chemokines MIP-1alpha, MIP-1beta, and RANTES do not reflect the disease course in HIV-seropositive individuals. (2000) (8)
Somatic hypermutation and mRNA expression levels of the BCL‐6 gene in patients with hepatitis C virus‐associated lymphoproliferative diseases * (2007) (8)
Integrated safety analysis of Sofosbuvir-based HCV treatment regimens from phase 3 studies (2014) (8)
Chemokine mRNA levels in mononucleated cells of HIV-infected patients before and after initiation of PI- versus NNRTI-containing HAART. (2004) (8)
Semiquantitation of human chemokine mRNA levels with a newly constructed multispecific competitor fragment. (1999) (8)
Influence of genetic variations in the SOD1 gene on the development of ascites and spontaneous bacterial peritonitis in decompensated liver cirrhosis (2017) (8)
Early viral kinetics do not predict treatment outcome with sofosbuvir+ribavirin for 12 or 24 weeks in HCV genotype 2/3 patients in the valence trial (2014) (8)
Early versus delayed treatment of acute hepatitis C: Final results of the randomized controlled German HEP-NET acute HCV-III study (2012) (8)
Liver Fibrosis—From Mechanisms of Injury to Modulation of Disease (2022) (8)
Between Scylla and Charybdis: the role of the human immune system in the pathogenesis of hepatitis C. (2013) (8)
Circulating levels of PRO-C3 reflect liver fibrosis and liver function in HIV positive patients receiving modern cART (2019) (8)
Review article: HCV ? STAT-C era of therapy (2010) (8)
Azathioprine With Budesonide Induces Remission More Effectively Than With Prednisone in Patients With Autoimmune Hepatitis (2010) (7)
Fifteen years of Env C2V3C3 evolution in six individuals infected clonally with human immunodeficiency virus type 1 (2007) (7)
Cytotoxic capacity of hepatitis C virus (HCV)–specific lymphocytes after in vitro immunization with HCV‐derived lipopeptides (2005) (7)
Liver histopathology in human immunodeficiency virus–hepatitis C virus co‐infected patients with fatal liver disease (2005) (7)
Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization (2022) (7)
Daclatasvir plus Sofosbuvir with or without Ribavirin for the Treatment of Chronic HCV Infection in Patients with Decompensated Cirrhosis: Results of a European Multicentre Compassionate Use Program (2016) (7)
Survival and HLA-B*57 in HIV/HCV Co-Infected Patients on Highly Active Antiretroviral Therapy (HAART) (2015) (7)
Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severity (2015) (7)
Presentation of the HCV-derived lipopeptide LP20-44 by dendritic cells enhances function of in vitro-generated CD4+ T cells via up-regulation of TLR2. (2006) (7)
Effects of the CCR5-Δ32 Mutation on Hepatitis C Virus-Specific Immune Responses in Patients with Haemophilia (2009) (7)
Correlation of transient elastography with APRI and FIB‐4 in a cohort of patients with congenital bleeding disorders and HCV or HIV/HCV coinfection (2010) (7)
Hepatitis B virus subgenotype F3 reactivation with vaccine escape mutations: A case report and review of the literature (2018) (7)
Effects of the CCR5-Δ32 Mutation on Hepatitis C Virus-Specific Immune Responses in Patients with Haemophilia (2009) (7)
Hepatitis C virus-induced secretion of inflammatory chemokines preferentially recruits NKG2A+CD8+ T cells. (2008) (7)
Transient elastography discloses identical distribution of liver fibrosis in chronic hepatitis C between HIV-negative and HIV-positive patients on HAART. (2009) (7)
The PNPLA3 I148M variant promotes lipid-induced hepatocyte secretion of CXC chemokines establishing a tumorigenic milieu (2019) (7)
Rapid determination of the Delta32 deletion in the human CC-chemokine receptor 5 (CCR5) gene without DNA extraction by lightcycler real-time polymerase chain reaction. (2004) (6)
PS-177-HSD17B13 rs72613567 TA is associated with a reduced risk for developing hepatocellular carcinoma in patients with alcohol-related cirrhosis (2019) (6)
Successful transplantation of a liver from a donor with fatal ethylene glycol poisoning (2005) (6)
[Fatty liver and increased serum lactate in a woman with HIV]. (2003) (6)
48 EARLY VERSUS DELAYED TREATMENT OF ACUTE HEPATITIS C: FINAL RESULTS OF THE RANDOMIZED CONTROLLED GERMAN HEP-NET ACUTE HCV-III STUDY (2012) (6)
Augmentation of 17-1A–Induced Antibody-Dependent Cellular Cytotoxicity by the Triple Cytokine Combination of Interferon-&agr;, Interleukin-2, and Interleukin-12 (2000) (6)
381 A Multicenter Analysis of Antiviral Response After One Year of Tenofovir Mono-Therapy in HBV-Monoinfected Patients with Prior Nucleos(t)ide Analog Experience (2008) (6)
Liver Disease Associated with Viral Infections (2011) (6)
Tenofovir disoproxil fumarate (TDF) versus emtricitabine plus TDF (FTC/TDF) for treatment of chronic hepatitis B (CHB) in patients with persistent viral replication receiving adefovir dipivoxi (2008) (6)
125 IL28B POLYMORPHISM IS ASSOCIATED WITH JAUNDICE DURING ACUTE HCV INFECTION AND IS A STRONG PREDICTOR FOR SPONTANEOUS CLEARANCE IN THE PROSPECTIVE GERMAN ANTI-D COHORT (2010) (6)
Prestimulation of monocytes by the cytokines GM-CSF or IL-2 enhances the antibody dependent cellular cytotoxicity of monoclonal antibody 17-1A. (2000) (6)
Primary immunisation of hepatitis C virus (HCV)-specific antibody producing B cells by lipidated peptides. (2004) (6)
A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms (2019) (6)
Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicities. (2021) (5)
Daclatasvir plus Sofosbuvir with or without Ribavirin for Treatment of Chronic HCV Infection in Patients with Advanced Liver Disease: Results of a European Compassionate use Program (2016) (5)
Use of beta-blockers is associated with improved 30 day survival in patients with spontaneous bacterial peritonitis (2015) (5)
Effect of cytochrome P450 induction on phosphorus metabolites and proton relaxation times measured by in vivo 31P‐magnetic resonance spectroscopy and 1H‐magnetic resonance relaxometry in human liver (1997) (5)
Differential expansion of T‐cell receptor variable beta subsets after antigenic stimulation in patients with different outcomes of hepatitis C infection (2002) (5)
Transient elastography discloses identical distribution of liver fibrosis in chronic hepatitis C between HIV-negative and HIV-positive patients on HAART (2010) (5)
A genetic variant in toll-like receptor 5 is linked to chemokine levels and hepatocellular carcinoma in steatohepatitis (2021) (5)
IL-28B Genetic Variants Determine the Extent of Monocyte-Induced Activation of NK Cells in Hepatitis C (2016) (5)
Endogenous levels of C-C chemokines MIP-1α, MIP-1β, and RANTES do not reflect the disease course in HIV-seropositive individuals (2000) (5)
CCR5-Δ32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection (2013) (5)
[Orthotopic liver transplantation in a 33-year-old patient with fulminant hepatitis B and HIV infection]. (2000) (5)
929 EVALUATION OF SAFETY AND TOLERABILITY OF TENOFOVIR DF (TDF) LONG TERM MONOTHERAPY IN NUCLEOS(T)IDE ANALOGUE EXPERIENCED PATIENTS WITH HBV MONOINFECTION (2009) (5)
559 Individualized treatment strategy with peginterferon alpha-2b (PEG-IFN a) plus ribavirin according to early viral kinetics in hepatitis C virus (HCV) type 1 infected patients (2006) (5)
Structured treatment interruptions following immediate initiation of HAART in eight patients with acute HIV-1 seroconversion. (2006) (5)
Risk of Hepatitis C After Immunoadsorption (2002) (5)
norUrsodeoxycholic acid (norUDCA) improves cholestasis in primary sclerosing cholangitis (PSC) independent of ursodeoxycholic acid (UDCA) pre-treatment and response (2016) (5)
[Monoethylglycinexylidide (MEGX)-test. A test for the assessment of prognosis before and after liver transplantation]. (2008) (4)
Importance of minimal residual viremia for relapse prediction in patients with chronic hepatitis C genotype 1 infection. (2011) (4)
Gallbladder emptying during high-dose cholecystokinin infusions. Effect in patients with gallstone disease and healthy controls. (1995) (4)
Host genetic factors and treatment of hepatitis C. (2008) (4)
Hepatic Toxicity of Antiviral Agents (2007) (4)
544 A EUROPEAN FIELD STUDY OF THE EFFICACY AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) AS MONOTHERAPY IN PATIENTS WITH PRIOR FAILURE TO OTHER NUCLEOSIDE/NUCLEOTIDE ANALOGUES (2012) (4)
633 Enhanced expression of CD94/NKG2A on CD8+ T lymphocytes from HCV-positive patients (2003) (4)
Surface expression and cytolytic function of NK cell receptors is altered in chronic hepatitis C (2005) (4)
Renal Functional Reserve is Well Maintained in Patients with Advanced Liver Cirrhosis and Ascites (2002) (4)
Liver Disease Associated with Non-Hepatitis Viruses (2019) (4)
1028 RENAL SAFETY AND ANTIVIRAL EFFICACY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) MONOTHERAPY IN NUCLEOS(T)IDE ANALOGUE REFRACTORY PATIENTS WITH HEPATITIS B VIRUS (HBV) MONO-INFECTION (2010) (4)
296 Importance of ribavirin dosage on virological response rates in patients chronically infected with hepatitis C virus and treated with interferon-based combination therapy (2003) (4)
NK Cells in Ascites From Liver Disease Patients Display a Particular Phenotype and Take Part in Antibacterial Immune Response (2019) (4)
Elective Surgery but not Transjugular Intrahepatic Portosystemic Shunt Precipitates Acute‐On‐Chronic Liver Failure (2021) (4)
[Liver biopsy at the intersection of clinical and pathological diagnosis]. (2008) (3)
Re-evaluation of the genetic cirrhosis risk score in patients with chronic hepatitis C virus infection (2009) (3)
Increased frequency of the CC-chemokine receptor 5-D32/D32 genotype in hepatitis C (2001) (3)
Neither black nor white: do altered intestinal microbiota reflect chronic liver disease severity? (2020) (3)
E2 antibodies mediate antibody dependent cellular cytotoxicity in HCV (2000) (3)
Unravelling complexity--the scientific basis of genetic predisposition in autoimmune liver disease. (2001) (3)
Which lidocaine dose should be used for the MEGX liver function test? (1995) (3)
Reply to: "Controversy on the role of FoxP3⁺ regulatory T cells in fibrogenesis in chronic hepatitis C virus infections". (2014) (3)
408 Binding of the hepatitis C virus envelope E2 protein to CD81 results in reduced responsiveness of CD8+ lymphocytes to CC chemokines (2004) (3)
Addition of pegylated interferon alfa-2a to an ongoing nucleos(t) ide treatment accelerates decrease of HBs-antigen levels in patients with chronic hepatitis B: Results from the PADD-ON study (2018) (3)
Sa1041 Triple Therapy Under Real Life Conditions: Telaprevir (TVR) and Boceprevir (BOC) in Combination With Peginterferon-Alfa-2A Plus Ribavirin (P/R) in Treatment Experienced Patients Infected With Chronic Hepatitis C, Genotype 1. the PAN Study (2013) (3)
Six weeks of Sofosbuvir/Ledipasvir treatment of acute hepatitis C Virus genotype 1 monoinfection: Final results of the German HepNet Acute HCV IV Study (2016) (3)
1172 GENETIC VARIATION IN IL28B RS 12979860 AND RESPONSE TO HCV-SPECIFIC TREATMENT IN HCV/HIV CO-INFECTED PATIENTS (2010) (3)
Hepatitis C virus‐associated mixed cryoglobulinaemia (1997) (3)
Course and therapy of acute liver failure. (2008) (3)
928 EFFECTIVENESS OF TENOFOVIR DF (TDF) MONOTHERAPY IN PATIENTS WITH PRIOR EXPERIENCE TO NUCLEOSIDE/NUCLEOTIDE ANALOGUES BY DIFFERENT PATTERN OF PRE-EXISTING MUTATIONS (2009) (3)
[Antineutrophil cytoplasmatic antibodies and their diagnostic significance as serum markers]. (2008) (3)
HIV/HCV coinfection, HAART, and liver-related mortality (2004) (3)
Efficacy and safety of tenofovir disoproxil fumarate (TDF) monotherapy in a European multicenter cohort of nucleos(t)ide experienced patients with chronic hepatitis B virus (HBV)-infection (2010) (2)
[Liver cirrhosis as precancerous conditions]. (1997) (2)
Treatment of acute hepatitis B with lamivudine vs. placebo: A prospective randomized multicenter trial (2013) (2)
Non-invasive fecal microbiota transplantation for recurrent Clostridium difficile infection in a patient presenting with hypertensive disorder post interventionem (2016) (2)
Effect of HAART on liver-related mortality in patients with HIV/HCV coinfection (2004) (2)
[HIV-infection: modern antiretroviral therapy]. (2004) (2)
Es-Citalopram for the prevention of PEG-IFN-α and Ribavirin associated depression in HCV-infected patients without psychiatric risk factors (CIPPAD-study) (2009) (2)
Survival after 131I-labeled lipiodol therapy for hepatocellular carcinoma (2014) (2)
[Non adherence - non response in transplantation medicine]. (2010) (2)
Late-breaking abstracts (2007) (2)
Chemokine Receptor ( CCR ) 1 and CCR 5 Surface Expression on Peripheral Blood T Lymphocytes from Patients with Chronic Hepatitis C Infection (2002) (2)
Differences in the source sequence of two HCV genotype 1b outbreaks within immunodominant CD8 epitopes are associated with differential outcome (2010) (2)
[Occurrence and significance of autoantibodies in the course of interferon therapy of chronic hepatitis C]. (1996) (2)
Transient Loss of T-Cell Reactivity in a Patient with Hepatitis C Virus Reinfection (2001) (2)
In vitro cytopathogenicity of the human immunodeficiency virus (HIV)-1 predicts survival in HIV-infected hemophiliacs independent from CD4 cell count. (1998) (2)
[Ursodeoxycholic acid in primary biliary cirrhosis. 2: Prospective long-term study of 21 patients]. (1988) (2)
[Hepatitis and posthepatic cirrhosis in AIDS]. (1995) (2)
Präsidentenposter: Early versus delayed treatment of acute hepatitis C: The German HEP-NET acute HCV-III study – a randomized controlled trial (2009) (2)
Host Genetic Factors and Treatment of Hepatitis C (2008) (2)
[Progress of acute liver failure and indications for liver transplantation]. (2008) (2)
Ursodeoxycholic acid improves cholestasis in primary sclerosing cholangitis (2017) (2)
Single Nucleotide Polymorphisms Associated With Alimentary Fatty Liver Disease Are Not Genetic Risk Factors For Treatment-associated Hepatic Steatosis in HIV Patients On HAART (2013) (2)
Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy. (2013) (2)
THU-492-Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma (2019) (2)
nor Ursodeoxycholic acid improves cholestasis in primary sclerosing cholangitis (2017) (2)
875 REAL-WORLD EFFICACY AND SAFETY OF BOCEPREVIR IN COMBINATION WITH PEGINTERFERON alfa-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS: INTERIM ANALYSIS FROM THE GERMAN NON-INTERVENTIONAL PAN STUDY (2013) (1)
1345 INTERACTION BETWEEN IL28B CCR5Δ32, AND HCV PERSISTENCE WITH GBV-C VIREMIA AND SYMPTOMS DURING ACUTE INFECTION (2011) (1)
1092 EFFECTS OF PRE-TREATMENT WITH BEZAFIBRATE FOLLOWED BY STANDARD OF CARE IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1 INFECTION AND ELEVATED GGT LEVELS (2012) (1)
1390 a1-ANTITRYPSIN PiMZ-MUTATION AND ALCOHOLIC STEATOHEPATITIS ARE BI-DIRECTIONALLY AGGRAVATING AMPLIFIERS IN CHRONIC LIVER DISEASE (2013) (1)
TLR-activated monocytes express IFN-lambda receptor 1 and trigger IFN-gamma secretion of NK cells after stimulation with IFN-lambda (2014) (1)
420 Reduced intrahepatic expression of DC-SignR in (2004) (1)
403 Induction of epitope-specific immune responses by hepatitis C virus (HCV)-derived lipopeptides using monocytes versus monocyte-derived dendritic cells (2004) (1)
816 THE TGF-β HIGH PRODUCER GENOTYPE IS ASSOCIATED WITH RESPONSE TO HCV-SPECIFIC THERAPY IN HIV-POSITIVE PATIENTS WITH ACUTE HEPATITIS C (2008) (1)
401 Increased rantes steady state MRNA levels in liver biopsies of HIV/HCV coinfected patients (2004) (1)
Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation (2021) (1)
CD8+ T cell selection pressure is a major driving force for evolution of hepatitis C virus nonstructural proteins (2011) (1)
[Chronic hepatitis C in type-II cryoglobulinemia and cutaneous vasculitis]. (1994) (1)
Differenzialdiagnose Ikterus (2009) (1)
Tips for severe hepatorenal syndrome in non-transplant cirrhotics: a new option?! (1998) (1)
P112: Hepatitis C virus NS3 polymorphism Q80K in genotype 1 therapy‐naive Brazilian patients (2015) (1)
409 The DC-signR tandem-repeat polymorphism in hepatitis C virus infection (2004) (1)
Frequency of Resistance to Commonly used Antibiotics among A German Cohort of Patients with Spontaneous Bacterial Peritonitis Challenges Current Treatment Recommendations (2016) (1)
Efficacy and Safety of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Virus Infection and Inherited Blood Disorders: Final Data from the C-Edge Ibld Study (2016) (1)
1351 PREDICTION OF RELAPSE AFTER PEGINTERFERON ALFA-2B/RIBAVIRIN THERAPY IN CHRONIC HCV GENOTYPE 1 PATIENTS IS DEPENDENT ON MINIMAL RESIDUAL VIREMIA BUT NOT ON IL28B GENOTYPE (2011) (1)
Which is the hen and which is the egg? (2000) (1)
Acute Hepatitis E Virus infection in a hemophilic patient with acquired inhibitor during immune tolerance therapy according to modified Bonn‐Malmö protocol (2019) (1)
Single-cell RNA sequencing identifies a population of human liver-type ILC1s (2023) (1)
232 TRAIL RECEPTOR I POLYMORPHISMS C626G AND A638C ARE ASSOCIATED WITH AN INCREASED RISK FOR THE DEVELOPMENT OF HEPATOCELLULAR CARCINOMA (HCC) IN HCV-INFECTED PATIENTS (2011) (1)
Carriage of HSD17B13 rs72613567TA is associated with a reduced risk for developing hepatocellular carcinoma in patients with alcohol-related cirrhosis (2019) (1)
908 REAL-WORLD EFFICACY OF BOCEPREVIR IN COMBINATION WITH PEGINTERFERON alfa-2a AND RIBAVIRIN IN TREATMENT-EXPERIENCED PATIENTS: INTERIM ANALYSIS FROM THE GERMAN NON-INTERVENTIONAL PAN STUDY (2013) (1)
Add on Interferon-Alpha-2a for the treatment of hbeag negative Hepatitis B patients receiving effective nucleos (t)ide therapy: interim results of the prospective multicentre padd-on trial (2016) (1)
Ribavirin in Acute Hepatitis E Infection in Patients with Gynecological Cancer: A Case Series (2018) (1)
Targeting mitochondrial dysfunction can restore antiviral activity of NK cells in HIV/HCV coinfection (2019) (1)
TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients (2012) (1)
[604] COMPARISON OF A SHORTENED RIBAVIRIN TREATMENT VS A 24 WEEK STANDARD COMBINATION THERAPY IN HCV INFECTED PATIENTS WITH GENOTYPE 2/3 (2007) (1)
Inflammatory Biomarkers in Ascites (2015) (1)
Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure. (2022) (1)
[Liver cirrhosis--2: Complications and treatment]. (2001) (1)
Rheumatological Patients are at Risk of Chronic HEV Infection: A Multicentric European Study (2016) (1)
[Nucleoside induced hepatopathy in HIV patients. Diagnostic value of liver biopsy assessment]. (2004) (1)
Influence of gender on cytokine induced depression and treatment: Gender aspects of IFN-α-induced depression. (2021) (1)
TLR agonists enhance responsiveness of inflammatory innate immune cells in HLA-B*57-positive HIV patients (2020) (1)
Reply to: "In HIV/HCV co-infected patients T regulatory and myeloid derived suppressor cells persist after successful treatment with directly acting antivirals". (2017) (1)
Effects of pre-treatment with bezafibrate followed by standard of care in treatment-naive patients with chronic hepatitis C genotype 1 infection and elevated GGT levels (2012) (1)
9 ASSOCIATION OF A GENETIC VARIANT OF THE TOLL-LIKE RECEPTOR 9 (TLR9) WITH SPONTANEOUS VIRAL CLEARANCE AND WITH INTERFERON RESPONSE IN CHRONIC HEPATITIS C VIRUS INFECTION (2013) (0)
IL-28B Genotype is not associated with early HCV-RNA negativity in patients with symptomatic acute HCV infection (2013) (0)
127 THE ACTIVATING NK CELL RECEPTOR NKP46 MAY BE INVOLVED IN ANTI-FIBROTIC ACTIVITY OF NK CELLS IN CHRONIC HEPATITIS C (2012) (0)
Endoscopic retrograde cholangiography in primary sclerosing cholangitis: A risk? (1990) (0)
P0678 : IL-8 producing CD4+ regulatory T cells stimulate angiogenesis in chronic hepatitis C (2015) (0)
[Conservative therapy of acute liver failure]. (1996) (0)
Hepatitis C virus core antigens induce apoptosis in CD4+ T-lymphocytes (2000) (0)
Reply to Godbole et al. (2018) (0)
Reply to: “Further evidence for the relevance of TLR2 gene variants in spontaneous bacterial peritonitis” (2012) (0)
LOW SERUM SELENIUM LEVELS IN ADVANCED-STAGE HIV-INFECTED PATIENTS (1994) (0)
G11 : Microbial translocation in liver fibrosis induces chronic IFNAR signaling that impairs innate immunity against bacterial infection (2015) (0)
Mitochondrial dysfunction contributes to impaired cytokine production of CD56 bright NK cells from HIV(+) individuals under effective antiviral therapy. (2022) (0)
703 EVIDENCE FOR DIFFERENTIAL ADAPTATION OF HEPATITIS C VIRUS IN POPULATIONS WITH DIFFERENT HLA-CLASS I-BACKGROUND (2010) (0)
788 INTERFERON-α MEDIATED ACTIVATION OF NATURAL KILLER CELLS IS ASSOCIATED WITH EFFICIENT INDUCTION OF APOPTOSIS OF ACTIVATED PRIMARY HUMAN HEPATIC STELLATE CELLS (2011) (0)
121 IMPACT OF MHC CLASS I-ASSOCIATED SELECTION PRESSURE ON THE EVOLUTION OF HCV NS3 IN A SINGLE-SOURCE OUTBREAK (2008) (0)
279 HCV CORE-INDUCED CXCL10 SECRETION LEADS TO RECRUITMENT OF CXCR3(+) NATURAL KILLER CELLS WITH LOW CYTOTOXIC POTENTIAL (2011) (0)
Does the interferon‐lambda rather than the interferon‐alpha pathway determine the outcome of hepatitis C virus infection? (2014) (0)
733 NEOEPITOPES DERIVED FROM EXTRACELLULAR MATRIX DEGRADATION REFLECT LIVER FUNCTION, FIBROSIS AND HVPG IN HIV-PATIENTS (2013) (0)
634 The tandem-repeat polymorphism of the DC-SIGNR gene in HCV infection (2003) (0)
427 Characterisation of HCV core-specific adaptive regulatory T cell clones from patients with chronic hepatitis C infection (2006) (0)
1335 IL28B POLYMORPHISM IN HIV-POSITIVE PATIENTS WITH ACUTE HEPATITIS C (2011) (0)
1121 EARLY MARKERS OF METABOLIC SYNDROME ARE ASSOCIATED WITH DISTINCT HCV GENOTYPES, WHILE ABNORMAL GLUCOSE TOLERANCE SUBSTANTIALLY DECREASES THE LIKELIHOOD OF SVR (2012) (0)
CXCR3(+)CD56Bright NK cells have strong anti-fibrotic potential. (2013) (0)
Hepatic disease. (1999) (0)
ANALYSIS OF IL28B GENOTYPE FOR THE SELECTION OF PATIENTS FOR AN INDIVIDUALIZED TREATMENT DURATION IN HCV GENOTYPE 1 PATIENTS (THE INDIV-1 STUDY) (2011) (0)
University of Birmingham norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis (2017) (0)
Method for identifying atypical p-ANCA (2004) (0)
[When does hepatitis C infection become chronic?]. (1997) (0)
30. HIV-Infektion (2017) (0)
Ascites NK cells are phenotypically distinct from blood and liver NK cells in patients with liver cirrhosis and become activated by bacterial stimulation in-vitro and during spontaneous bacterial peritonitis (2018) (0)
[456] NKG2A-POSITIVE CD8+ T CELLS IN CHRONIC HEPATITIS C (2007) (0)
[Abdominal colic, arthralgia, petechial skin hemorrhage and glomerulonephritis after a subtropical stay]. (1990) (0)
Ascites total protein may be modulated by the use of diuretics (2015) (0)
Genetic polymorphisms in fatty liver disease in HIV positive patients receiving combined antiretroviral therapy (cART) (2016) (0)
Association of genetic variants in innate immunity genes with spontaneous viral clearance and with interferon response in chronic hepatitis C virus infection (2013) (0)
Are pseudotumours of bone an additional risk factor for recurrent bacterial infection in HIV‐infected haemophiliacs? (1996) (0)
Outcome after Orthotopic Liver Transplantation in 33 Human Immunodeficiency Virus (HIV)-Positive Patients in Germany: Recurrence of Chronic Hepatitis-C Infection after Transplantation: 2103 (2012) (0)
P1136 TRIPLE THERAPY WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2a/RIBAVIRIN IN A REAL-LIFE SETTING: IS IT POSSIBLE TO ACHIEVE SVR RATES COMPARABLE TO PIVOTAL TRIALS? (2014) (0)
[Mycobacterium avium infection presenting as a mass in the right lung]. (2000) (0)
Transient elastography (FibroScan®) in patients with chronic hepatitis C infection and haemophilia A (2007) (0)
The RANTES (-403 G→A) promoter polymorphism does not affect HCV or HIV/HCV co-infection but is increased in HIV infection (2003) (0)
624 THE CTLA4 +49 A>G POLYMORPHISM AFFECTS RESPONSE TO HEPATITIS C VIRUS-SPECIFIC THERAPY IN HIV+ PATIENTS WITH ACUTE HEPATITIS C (2009) (0)
Dynamic role of human ILC3 in the regulation of hepatic fibrogenesis (2018) (0)
778 THE CD56BRIGHTCXCR3(+) PHENOTYPE CHARACTERIZES A DISTINCT NK CELL SUBSET WITH ANTI-FIBROTIC POTENTIAL THAT SHOWS DYS-REGULATED ACTIVITY IN HEPATITIS C (2012) (0)
The risk of bleeding after biopsy in special risk groups (1998) (0)
Differential T cell subset activation in patients with different outcomes of hepatitis C (1998) (0)
Impact of therapeutic, anthropometric and genetic factors on glucose metabolism in HIV‐patients – a reason for glycemic control? (2006) (0)
P143 ACTIVATED MONOCYTES EXPRESS IFN-λ RECEPTOR 1 AND EFFECTIVELY TRIGGER IFN-γ SECRETION OF NK CELLS AFTER STIMULATION WITH IFN-λ (2014) (0)
Identification and characterisation of a hepatic IL-13 producing ILC3-like population potentially involved in liver fibrosis. (2023) (0)
Cohort study evaluating predictors of therapeutic success after sleeve gastrectomy or Roux-en-Y gastric bypass (2021) (0)
Sa1052 Triple Therapy Under Real Life Conditions: Telaprevir (TVR) in Combination With Peginterferon-Alfa-2A Plus Ribavirin (P/R) in NaïVE Patients Infected With Chronic Hepatitis C, Genotype 1. The PAN Study (2013) (0)
P0700 : Immunological rather than virological response to haart is associated with improved anti-HCV NK cell activity in HIV patients (2015) (0)
Nitric oxide and renal functional reserve in compensated cirrhosis (1995) (0)
686 EXPANSION OF CXCR3 (+) NK CELLS WITH A LOW CYTOTOXIC POTENTIAL IN HEPATITIS C MAY BE ASSOCIATED WITH INEFFICIENT ANTI-VIRAL IMMUNE RESPONSE AND HCV-ASSOCIATED FIBROSIS (2010) (0)
624 HEPATITIS C VIRUS INFECTION ALTERS SERUM LEVELS OF THE MAJOR TYPE III INTERFERON IL-29 (2008) (0)
881 ALTERED EXPRESSION OF DEATH RECEPTORS AND THEIR LIGANDS AS A MECHANISM FOR ENHANCED CD4+ T CELL APOPTOSIS IN HIV/HCV CO-INFECTION (2009) (0)
Nuclear localisation of hepatitis C virus (HCV) NS2 protein in human epithelial cell lines (2000) (0)
[Anaphylaxis due to contrast media]. (2000) (0)
694 HLA CLASS I ALLELES ASSOCIATED WITH HCV POLYMORPHISMS AND RESPONSE TO ANTIVIRAL THERAPY IN HCV GENOTYPE 1-INFECTED PATIENTS (2010) (0)
Binding of HCV E2 to CD81 enhances surface expression of HLA-E (2003) (0)
P747 ASSOCIATION OF A GENETIC VARIANT OF THE MITOCHONDRIAL ANTIVIRAL SIGNALING PROTEIN (MAVS) WITH INTERFERON RESPONSE IN CHRONIC HEPATITIS C VIRUS INFECTION (2014) (0)
Non-invasive fecal microbiota transplantation for recurrent Clostridium difficile infection in a patient presenting with hy- pertensive disorder post interventionem Nicht-invasive fäkale Mikrobiota-Transplantation bei einem Patienten mit rekurrierender Clostridium difficile Infektion und hypertensi (2016) (0)
A comparison of the expression of COX2, E-cadherin, β-catenin and Ki67 in FAP and sporadic adenomas (2001) (0)
High SVR 12 rates following treatment with direct acting antiviral agents (DAA) in a German multicentre cohort of HCV/HIV-1 coinfected patients on the transplant waiting list with advanced liver cirrhosis (2017) (0)
[Ursodeoxycholic acid in primary biliary cirrhosis. 1: Therapeutic approaches up to now and the rationale for treatment with ursodeoxycholic acid]. (1988) (0)
Microbial translocation in liver fibrosis induces chronic IFNAR signaling that directly affects innate immune responses to systemic bacterial infection (2015) (0)
CELLS AND HEPATIC STELLATE CELLS ( HSC ) BY ACTING ON EITHER CELL TYPE (2014) (0)
Higher intrahepatic IFNγ and TNFA mRNA levels are linked to non-response to IFNA therapy for chronic hepatitis C (2000) (0)
Promising long-term efficacy of palliative tips treatment for hepatorenal syndrome in nontransplantable cirrhotics (1998) (0)
Virus-like particles in a case of acute hepatitis with human GB virus-C viraemia (2001) (0)
The antibody dependent cellular cytotoxicity (ADCC) of monoclonal antibody BR55-2 against the colorectal tumor cell line HT29 is augmented by the cytokines IFN-γ and IL-2 (1995) (0)
884 CXCL1 RS4074 POLYMORPHISM INFLUENCES THE SUSCEPTIBILITY TO HEPATOCELLULAR CARCINOMA (2010) (0)
Enteric dysfunction in patients with asymptomatic HIV-infection versus patients with hypoproteinemia/hypalbuminemia and advanced HIV-infection. (2002) (0)
P113: Influence of liver normoxia on intra‐ and extra‐hepatic NK cell function in HCV infection (2015) (0)
331 CO-STIMULATION VIA CD27 MIGHT IMPORTANTLY CONTRIBUTE TO ANTI-HCV ACTIVITY OF NK CELLS (2013) (0)
609 ADHESION OF NATURAL KILLER (NK) CELLS TO EXTRACELLULAR MATRIX IS CRITICALLY REGULATED BY HCV 2/CD81 INTERACTIONS (2008) (0)
Der Tandem-Repeat Polymorphism des DC-SIGNR Gens in der Hepatitis C Virus Infektion (2004) (0)
894 HLA-E-RESTRICTED RECOGNITION OF A HCV- DERIVED PEPTIDE BY HUMAN CD8(+) CYTOLYTIC T LYMPHOCYTES (2009) (0)
Syddansk Universitet Novel Rat Model of Repetitive Portal Venous Embolization Mimicking Human Non-Cirrhotic Idiopathic Portal Hypertension (2016) (0)
Chemokine expression in fulminant hepatitis (2000) (0)
[Chronic increased cholestasis parameters and sonographic echogenic round liver lesions in a clinically healthy male]. (1989) (0)
Circulating levels of Pro-C3 reflect liver fibrosis and function in HIV positive patients receiving cART (2016) (0)
Autoimmune Hepatitis is Associated with Stable Immunization against Intestinal Commensal Bacteria (2016) (0)
Immunodominant hepatitis C virus core epitopes stimulate CD3+CD30+ lymphocytes for productiuon of tho-like cytokines in patients with chronic hepatitis C (1995) (0)
[Do polymorphisms of the SDF1 and CCR2b genes modify the course of hepatitis C or HIV/HCV co-infection?]. (2002) (0)
M1752 Common Variants in the NOD2 Gene Are Associated with IL-8 Levels in Patients with Advanced Liver Disease - a Prospective Single Center Survival Study (2008) (0)
Influence of cytokines, monoclonal antmodies and chemotherapeutic drugs on epcam and lewisY antigen expression of colorectal carcinoma cell lines (2000) (0)
298 ESCITALOPRAM FOR THE PREVENTION OF PEG-IFN-α AND RIBAVIRIN ASSOCIATED DEPRESSION IN HCV-INFECTED PATIENTS: FINAL RESULTS FROM THE CIPPAD-TRIAL (2010) (0)
Sa1050 Efficacy of Boceprevir Based Triple Therapy in Combination With Peginterferon-Alfa-2A Plus Ribavirin (P/R) Under Real Life Conditions in Treatment Experienced Patients Infected With Chronic Hepatitis C, Genotype 1: The PAN Study (2013) (0)
People living with HIV, HCV and HIV/HCV coinfection in intensive care in a German tertiary referral center 2014-2019. (2023) (0)
Formation of iso-ursodeoxycholic acid during administration of ursodeoxycholic acid in healthy subjects (1990) (0)
359 HLA FOOTPRINTS IN HIV/HCV CO-INFECTED PATIENTS (2013) (0)
Human intrahepatic ILC3 may modulate hepatic stellate cell activation (2019) (0)
[Diagnosis of acute liver failure]. (1996) (0)
Low-density lipoprotein receptor polymorphisms are associated with spontaneous and treatment-induced recovery from hepatitis C virus infection (2008) (0)
882 SELECTIVE INDUCTION OF ADAPTIVE REGULATROY T-CELLS IN CHRONIC HEPATITIS C (2009) (0)
Common variants in the NOD2 gene are associated with elevated IL-8 levels and ascitic decompensation in patients with advanced liver cirrhosis (2010) (0)
Polymorphsims in the farnesoid X receptor modify the risk for spontaneous bacterial peritonitis in cirrhotic patients (2014) (0)
Contents Vol. 52, 2008 (2008) (0)
Sa1072 Early Markers of Metabolic Syndrome are Associated With Distinct HCV Genotypes, While Abnormal Glucose Tolerance Substantially Decreases the Likelihood of SVR (2012) (0)
P6: Prevalence of HCV, HBV and HIV infections among hemophiliac (2014) (0)
438 HCV E2/CD81 interactions alter migration of dendritic cells in chronic hepatitis C (2006) (0)
expression of costimulatory molecules B7-1, B7-2 and CD28 in primary biliary cirrhosis (1997) (0)
Hepatitis C virus (HCV) core protein does not inhibit Fas-induced apoptosis in human Hep G2 cells (1998) (0)
Circulating levels of endotrophin and cross-linked type III collagen reflect liver fibrosis in people with HIV (2023) (0)
Complications of Liver Cirrhosis: International Falk-Workshop, Bonn, February 1998 (1998) (0)
Effect of anti - retroviral therapy on liver-related mortality in HIV/HCV coinfected patients (2002) (0)
FRI-050-Antibodies to human beta-tubulin isotype 5 in autoimmune liver disorders-re-evaluation of their specificity and clinical relevance (2019) (0)
P160: Study of human liver fibrogenesis using human liver slices culture as a model (2015) (0)
Human immunodeficiency virus infection does not alter T cell immune response to hepatitis C (1998) (0)
Intrahepatic expression of interleukin-10 mRNA in chronic liver disease (1995) (0)
440 NKP46HIGH AND NKP46DIM EXPRESSION DEFINES PHENOTYPICALLY AND FUNCTIONALLY DIFFERENT HUMAN NK CELL SUBSETS THAT ARE ALTERED IN CHRONIC HEPATITIS C (2010) (0)
[HIV-associated cholangiopathy]. (1994) (0)
RANTES (−403 G→A) promoter polymorphism in HCV and HIV/HCV co-infection (2003) (0)
G 2 – Chronische Hepatitis (2007) (0)
3 POPULATIONAL ANALYSIS REVEALS A LINK BETWEEN COMPLEX VIRAL ESCAPE FROM CD8+ T-CELL RESPONSES AND PROTECTION IN HCV INFECTION (2011) (0)
University of Impact of rifaximin on the frequency and characteristics of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites (2014) (0)
120 HEPATITIS C VIRUS-INDUCED SECRETION OF INFLAMMATORY CHEMOKINES PREFERENTIALLY RECRUIT NKG2A EXPRESSING CD8+ T CELLS (2008) (0)
GBV-C co-infection in HIV patients downregulates CCR5 and CXCR4 surface expression on CD4 cells (2007) (0)
782 Anti-apoptotic function of gelsolin in FAS-antibody induced acute liver failure (2003) (0)
[596] GENOTYPE-SPECIFIC ASSESSMENT OF PREDICTIVE FACTORS FOR SUSTAINED VIROLOGIC RESPONSE AFTER STANDARD TREATMENT IN PATIENTS CHRONICALLY INFECTED WITH HCV (2007) (0)
CLINICAL—LIVER, PANCREAS, AND BILIARY TRACT Budesonide Induces Remission More Effectively Than Prednisone in a Controlled Trial of Patients With Autoimmune Hepatitis (2010) (0)
G 1 – Akute Virushepatitis (2007) (0)
311 HLA-B*07-POSITIVE INDIVIDUALS FROM A COMMON SOURCE HCV OUTBREAK ARE PREFERENTIALLY INFECTED BY A VIRAL VARIANT WITH A SUBSTITUTION IN AN HLA-B7-RESTRICTED CD8 EPITOPE (2011) (0)
The Spectrum of Malignancies in the Era of HAART (2009) (0)
625 POLYMORPHISMS IN TOLL-LIKE RECEPTORS 1 AND 2 ARE NOT ASSOCIATED WITH HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS C (2008) (0)
A pro-inflammatory variant in the TLR5 gene is associated with hepatocellular carcinoma in patients with cirrhosis due to steatohepatitis. (2020) (0)
121 CD40L induced fulminant hepatitis is abrogated in CD40 knockout mice (2006) (0)
Escitalopram for the prevention of peginterferon alpha-2a- and ribavirin-associated depression in HCV-infected patients without prior psychiatric disease: A randomized controlled trial (2012) (0)
[Interferons as therapy in viral hepatitis: are promises kept?]. (1995) (0)
Effects of HCV core-derived T helper lipopeptides on HCV-specific lymphocyte proliferation (1998) (0)
Survival after 131I-Lipiodol therapy of hepatocellular carcinoma across BCLC stages: A single center study (2013) (0)
Over-responsiveness of the IL-6/STAT3 pathway in inflammatory CD4+ T cells of patients with primary sclerosing cholangitis (2022) (0)
Copy number variation of the CCL3L1 gene in chronic HCV infection: Influence on susceptibility and fibro-inflammatory response (2007) (0)
P0217 : Use of beta-blockers at the onset of spontaneous bacterial peritonitis may be beneficial due to modulation of immune response (2015) (0)
Continuation of metformin use after a diagnosis of cir- rhosis significantly improved survival of patients with type II diabetes (DM) (2013) (0)
Hepatitis E in Haematological Patients in Europe: A Multicentre Study (2016) (0)
Sa1051 Boceprevir Based Triple Therapy in Combination With Peginterferon-Alfa-2A Plus Ribavirin (P/R) Under Real Life Conditions in Treatment NaïVE Patients Infected With Chronic Hepatitis C, Genotype 1: An Interim Analysis At Week 12 After Start of Treatment (2013) (0)
[The prevention of Pneumocystis carinii pneumonia in HIV infection]. (2008) (0)
Immunosuppressive effects of bile and bile acids on natural killer cell activity (2016) (0)
[The therapy of viral hepatitis in HIV-infected patients]. (1995) (0)
[455] INHIBITION OF ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC) DUE TO HCV CORE AA35-44 INDUCED STABILISATION OF HLA-E EXPRESSION (2007) (0)
441 HCV CORE-SPECIFIC ADAPTIVE CD4+ REGULATORY T CELL CLONES IN CHRONIC HEPATITIS C ARE HIGHLY SUSCEPTIBLE TO INHIBITION BY RIBAVIRIN (2010) (0)
Safety of add on Interferon-alpha-2a in hepatitis B patients receiving effective nucleos(t)de therapy: Interim results from the German multicenter PADD-ON trial (2014) (0)
TLR agonists enhance responsiveness of inflammatory innate immune cells in HLA-B*57-positive HIV patients (2020) (0)
97 BILIARY STRICTURES AND RECURRENT DISEASE AFTER LIVER TRANSPLANTATION FOR PRIMARY SCLEROSING CHOLANGITIS – A LARGE, MULTICENTER COHORT ANALYSIS WITH LONG-TERM FOLLOW-UP (2013) (0)
338 NK CELL SECRETED IFN-g BLOCKS HCV REPLICATION AND MAY PROMOTE SPONTANEOUS CLEARANCE OF ACUTE HEPATITIS C IN HIV(+) PATIENTS (2013) (0)
[Tuberculosis--current therapeutic concepts]. (2005) (0)
Autoimmune Hepatitis is Associated with Significant Alterations of the Circulating Innate Lymphoid Cell Pool and Displays Elevated Markers of Bacterial Translocation (2016) (0)
P0471 : NKp46 and trail are the major NK cell receptors involved in anti-HCV activity of NK cells in vitro (2015) (0)
Letter to the EditorResponse to: Flow cytometric cell-mediated cytotoxicity assay (2007) (0)
Does development of cholestatic liver disease in HIV and hepatitis C coinfected hemophiliacs indicate an unfavorable prognosis (1995) (0)
439 HEPATITIS C CO-INFECTION SENSITIZES CD4+ T CELLS TOWARDS FAS-INDUCED APOPTOSIS IN HIV-POSITIVE PATIENTS (2010) (0)
Enhanced intrahepatic chemokine expression as a possible mediator offulminant hepatic failure (2000) (0)
Enhanced expression of IFNγ and IL-1β but not of IL10 in fulminant hepatic failure (2001) (0)
Lack of NKp80 expression define a liver-resident CD49a(+) NK cell subset with ILC1-like features (2016) (0)
P159: Phenotype and functions of NK cells are significantly altered in HIV/HCV co‐infection (2015) (0)
S2083 Correlation of TRANSIENT ELASTOGRAPHY with APRI and Fib-4 in a Cohort of Patients with Congenital Bleeding Disorders and HCV Infection or HIV/HCV Co-Infection (2009) (0)
Orthotopic Liver Transplantation in Human Immunodeficiency Virus (HIV)-Positive Patients in Germany (2011) (0)
FRI-208-Predictors of treatment response during addition of pegylated Interferon alfa-2a to an onging nucleos (t)id treatment in chronic hepatitis B: Results from the PADD-ON trial (2019) (0)
Stimulation of angiotensin 1- and thromboxane A2-receptors of human hepatic arteries indicate a receptor-specific mechanism for the vascular hyporesponsiveness in cirrhosis (2001) (0)
P485 THE RATIO OF ASCITES CALPROTECTIN TO TOTAL PROTEIN IS A DIAGNOSTIC AND PROGNOSTIC MARKER FOR SPONTANEOUS BACTERIAL PERITONITIS IN LIVER CIRRHOSIS (2014) (0)
' s response to reviews Title : TRAIL receptor I ( DR 4 ) polymorphisms C 626 G und A 638 C are associated with an increased risk for hepatocellular carcinoma ( HCC ) in HCV-infected patients (2011) (0)
P0484 : CD3(+)CD56(+) NK-like T cells show reduced anti-viral activity in acutely HCV/HIV infected patients (2015) (0)
HIV-associated microbial translocation may affect cytokine production of CD56bright NK cells via stimulation of monocytes. (2022) (0)
[Eosinophilic esophagitis]. (2008) (0)
958 EXTRAHEPATIC MALIGNANCIES AFTER LIVER TRANSPLANTATION FOR PRIMARY SCLEROSING CHOLANGITIS – A LONG-TERM FOLLOW-UP OBSERVATIONAL STUDY OF A LARGE, MULTICENTER COHORT (2013) (0)
Final Results of a roll-over study (107) with Telaprevir, Peginterferon Alfa-2A and Ribavirin in Prior Null Response, Partial Response, Viral Breakthrough or Relapse HCV Genotype 1 Patients After PR (2011) (0)
324 TLR-2 ACTIVATION WITH HCV CORE AND NS3 ENHANCES PROANGIOGENIC DIFFERENTIATION OF HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS (2012) (0)
791 RIBAVIRIN EXERTS DIFFERENTIAL EFFECTS ON FUNCTIONS OF CD4+ TH1, TH2, AND REGULATORY T CELL CLONES IN HEPATITIS C (2012) (0)
A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms (2019) (0)
OVERWEIGHTHIV PATIENTSWITHABDOMINALFATDISTRIBUTION TREATEDWITHPROTEASEINHIBITORSAREATHIGHRISKFOR ABNORMALITIESINGLUCOSEMETABOLISM- A REASONFORGLYCEMICCONTROL (2008) (0)
Transient flare of psoriasis under direct‐acting antiviral therapy of chronic hepatitis C: A case report (2022) (0)
[Progressive multifocal leukoencephalopathy]. (1999) (0)
Down-regulation of CCR5 expression by hepatitis C virus (2003) (0)
598 The IL6 high producer (HP) genotype (IL6 +174G/G, and +174G/C) is associated with treatment-induced recovery from acute hepatitis C infection in HIV-infected patients (2006) (0)
Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA) (2019) (0)
Real World Experience of Prescribing Tenofovir Alafenamide for Chronic Hepatitis B Patients in Germany (2019) (0)
Gelsolin has anti-apoptotic function in fas-antibody induced fulminant hepatic failure (2003) (0)
[464] HCV CORE PROTEIN INDUCES CYTOKINE SECRETION AND PROLIFERATION IN TLR2 POSITIVE HEPATOMA CELLS (2007) (0)
Enhanced intrahepatic MxA expression in-fulminant hepatitis (1998) (0)
P730 ADVERSE EVENTS AND CO-MEDICATION: A COMPARISON BETWEEN DUAL- AND TRIPLE-COMBINATION THERAPIES IN GENOTYPE 1 PATIENTS WITH CHRONIC HEPATITIS C (2014) (0)
[Primary sclerosing cholangitis - challenges for all. The German Study Group PSC]. (2011) (0)
Portal and systemic serum concentrations of soluble tumor necrosis factor receptor p55 and p75 and of endotoxin in relation to portal vascular resistance (2000) (0)
247 HIGH LEVELS OF SOLUBLE TNF-ALPHA-RECEPTOR-I ARE ASSOCIATED WITH POOR OUTCOME IN CIRRHOSIS WITH PORTAL HYPERTENSION (2013) (0)
Production of tumor hecrosis factor alpha (TNF) and interferon-γ (IFN) by T-cells from patients with hepatitis B and C (1991) (0)
[Clinical aspects and diagnosis of hepatitis C]. (2000) (0)
CD4 regulatory T cells in hepatocellular carcinoma with different etiologies (2018) (0)
194 TIPS-PROCEDURE DOES NOT CHANGE ENDOTOXIN LEVELS IN BLOOD OF PATIENTS WITH ALCOHOLIC LIVER CIRRHOSIS (2011) (0)
Intrahepatic MDR3 P-glycoprotein mRNA expression in human primary billiary cirrhosis ? Evaluation by competitive polymerase chain reaction (1995) (0)
782 IMPAIRED CD4+ T CELL-MEDIATED STIMULATION OF NK CELL ANTI-FIBROTIC ACTIVITY MAY CONTRIBUTE TO ACCELERATED PROGRESSION TOWARDS HCV-ASSOCIATED LIVER FIBROSIS IN HIV/HCV CO-INFECTED PATIENTS (2012) (0)
A prospective multicenter pilot study to investigate the efficacy of pegylated Interferon-α2b and ribavirin in HBsAg+/HCV-RNA+ patients: The HEP-NET B/C coinfection trial (2008) (0)
693 DYS-REGULATED EXPRESSION OF THE SLAM FAMILY RECEPTOR CRACC AND CD48 ON NK CELLS IN CHRONIC HEPATITIS C (2010) (0)
The combination IFN-α/IL-2 and monoclonal antibody 17-1A induces a marked antibody dependent cellular cytotoxicity (ADCC) against the colorectal tumor cell line HT29 (1997) (0)
Cytokine expression and T-cell subset activation in chronic hepatitis C (1995) (0)
618 Prediction for treatment outcome in HCV type 1-infected patients: GAMMA-glutamyltranspepdidase (GGT) is the most reliable independent single parameter (2006) (0)
P127 CD4+ REGULATORY T CELLS (TREGS) MODULATE INTERACTIONS BETWEEN NK CELLS AND HEPATIC STELLATE CELLS (HSC) IN HEPATITIS C (2014) (0)
Subject Index Vol. 52, 2008 (2008) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Ulrich Spengler?

Ulrich Spengler is affiliated with the following schools:

University College London
Technical University of Munich
University of Bonn

Ulrich Spengler's Academic­Influence.com Rankings

Why Is Ulrich Spengler Influential?

Ulrich Spengler's Published Works

Published Works

What Schools Are Affiliated With Ulrich Spengler?

Ulrich Spengler's AcademicInfluence.com Rankings